Royalty Report: Drugs, Diagnostic, Therapeutic – Collection: 148361

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 9

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 9

Primary Industries

  • Drugs
  • Diagnostic
  • Therapeutic
  • Drug Discovery
  • Disease
  • Content
  • Medical Info
  • Assay
  • Imaging
  • Data Management
  • Molecular
  • Proteins

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 148361

License Grant
Licensor grants to Licensee
– the sole and exclusive worldwide right and license, with no right to sublicense under both the Licensors Technology and interest in any Joint Technology,  to use the Licensor Transporters for the identification   and/or development  of Lead Compounds and Collaboration Products in the Field of Use;

– the sole and exclusive worldwide right and license,  with the right to sublicense to Affiliates of Licensee and/or one or more Third Parties,  under both the Licensor Technology and interest in any Joint Technology,  to make, have made, use, import,  market,  offer for sale and sell Lead Compounds and Collaboration Products in the Field of Use;

– during the term of the Research Program, the sole and exclusive right and license, with no right to sublicense, under both the Licensor Ancillary Transporter Technology and interest in any Joint Technology,  to use the Licensor Ancillary Transporters  for the sole purpose of conducting selectivity testing of Lead Compounds and Collaboration Products;

– after the term of the Research Program, a non-exclusive right and license,  with no right to sublicense,  under the Licensor Ancillary Transporter Technology to use the Licensor  Ancillary Transporters for the sole purpose of conducting selectivity testing of Lead Compounds and Collaboration Products;

– during the term of this Agreement, a nonexclusive right and license, with no right to sublicense, to use all data and information generated by or on behalf of Licensor in the conduct of the Research  Program,  including data relating to Hits in the Licensor Proprietary Chemical Library, but only as shall be reasonably  necessary for Licensee to conduct research to identify and develop Lead Compounds and   Collaboration Products,  provided,  however,  that such license shall become sole and exclusive when a  Compound is designated a Lead Compound in accordance  with Article Six and shall revert to a non-exclusive  license  upon  determination  of  the  Steering Committee or  Licensee  that such Lead  Compound will not become a Collaboration Product;

– during the term of this Agreement, an exclusive right and license,  with the right to sublicense,  to use all data and information generated by or on behalf of Licensor in the conduct of the  Research Program  relating to Lead Compounds and/or Collaboration Products in the Licensor Proprietary Chemical Library,  but only as shall be reasonably necessary for Licensee to conduct research to identify and develop Lead Compounds and Collaboration Products; and

– during the term of this Agreement,  a non-exclusive right and license,  with no right to sublicense, to use the Licensor Materials but only to the extent that such right and license shall be necessary for Licensee to identify and develop Lead Compounds and Collaboration Products.

License Property
Licensor is the owner or licensee of certain patent rights relating to human glutamate transporters.

Glutamate transporters are a family of neurotransmitter transporter proteins that move glutamate – the principal excitatory neurotransmitter – across a membrane.

Licensor Transporters mean EAAT-2 and EAAT-3  protein of amino-acid compositions.

Field of Use
The field means all therapeutic, prophylactic and diagnostic uses.

IPSCIO Record ID: 223154

License Grant
For Ownership of Licensor Accessible Libraries and Licensor Patents, Licensor grants a worldwide, exclusive license, including the right to sublicense, in the Field under such patent to make, have made, use, sell, have sold, import and have imported Licensed Products, provided that Licensor is not contractually prohibited from granting such an exclusive license.  

For the License Under All Licensor Research Program Patents, Licensor grants a non-exclusive license in the Field under all Research Program Patents owned by Licensor to the extent such patents cover making, using, selling, offering for sale or importing a Qualified Lead Compound, an Active Compound or a Licensed Product.

License Property
Licensor DirectedDiversity(R) Technology means Licensor Patents and know-how in effect at the time of the Effective Date of this Agreement that relate to generating and utilizing a DirectedDiversity(R) Chemical Library,  including patents for System, method, and computer program product for at least partially automatically generating chemical compounds with desired properties from a list of potential chemical compounds to synthesize. This term also includes any discoveries, improvements, inventions and modifications made during the Research Program to the extent that they relate to Licensor DirectedDiversity(R) Technology.

DirectedDiversity® Chemical Library means a computer-generated library of compounds containing integrated structure•activity and synthesis data.

Active Compound means a Qualified Lead Compound or a compound derived from a Qualified Lead Compound that has been formally selected by Licensee after recommendation by the Research Steering Committee for preclinical development as evidenced by initiation of a Licensee supported range finding toxicology study to be performed by the Licensee Toxicology Department or its designate.

The Licensed Product means any commercial product containing an Active Compound.  

Licensor Accessible Libraries means anyDirectedDiversity® Chemical Library that is generated by Licensor outside of the Research Program.

Field of Use
The Field is human therapeutic and diagnostic uses of Qualified Lead Compounds or Active Compounds against Targets.

IPSCIO Record ID: 223145

License Grant
Licensor grants to Licensee such rights that it has to grant a worldwide, exclusive license, with right to sublicense, to develop, make, have made, use, sell, offer for sale, have sold, import and have imported Licensed Products, under any Patent Rights owned by Licensor that would otherwise be infringed by Licensee but for this license, including Research Program Patent Rights, and under the Know-how developed by Licensee relating to the Licensed Products, including the Research Program Know-how.

This DiscoverWorksâ„¢ agreement is a research and development collaboration to identify Initial Hits, Improved Hits, Program Lead Compounds and Pre-Clinical Lead Compounds active against selected targets, and suitable, if required, for medicinal chemistry optimization, that may be developed and commercialized.

License Property
The patents include System and method of automatically generating chemical compounds with desired properties, and, Microplate thermal shift assay apparatus for ligand development and multi-variable protein chemistry optimization.

Licensed Product means any commercial product containing an Active Compound as an active ingredient.

Active Compound means a Program Lead Compound or a Pre-Clinical Lead Compound identified in the course of the Research Program, or compound further optimized from such a Program Lead Compound or a Pre-Clinical Lead Compound.

Chemical Optimization means the design, synthesis and identification of Improved Hits, Program Lead Compounds and Pre-Clinical Lead Compounds using DiscoverWorksâ„¢ Technology and other technologies.

DiscoverWorks™ Technology means DirectedDiversity® Technology and ThermoFluor® Technology.

DirectedDiversity(R) Technology means the descriptions, figures and claims of the Patent Rights and associated proprietary Licensor Know-how used to identify potential therapeutic compounds.

ThermoFluor® Technology means the Patent Rights and associated proprietary Licensor Know-how used to evaluate ligand-binding parameters.

Field of Use
The Field means the research, development and commercialization of chemical compounds for use in therapeutic and diagnostic products, except for use in the treatment or cure of Hepatitis C Virus through March 7, 2003 in humans.

IPSCIO Record ID: 222558

License Grant
For the Compounds and Products, Licensor grants an exclusive license under the Licensor Technology and Licensors interest in the Collaboration Technology, exclusive even as to Licensor and its Affiliates, to make, have made, use, sell, offer to sell, import and export Agreement Products in the Territory. It is understood that such licenses shall include the right to conduct drug research and development, and the exclusive right to discover, develop, make, have made and use Agreement Compounds, during the term of this Agreement.

For the Collaboration Target-Specific Technology, Licensor grants an exclusive license, exclusive even as to  Licensor and its Affiliates, under all of Licensors interest in the Collaboration Target-Specific Technology for any and all purposes in the Territory, including the right to grant sublicenses.

For the Collaboration Platform Technology, upon conclusion of the Collaboration Term, the Parties each  grant, to the other a co-exclusive license under their respective interests in the Collaboration Platform Technology in the Territory, as follows  the Parties may each use such Collaboration Platform Technology for any and all internal uses, including without limitation, in collaboration with Third Parties for drug discovery.

For the Columbia Sublicense, Licensor grants a non-exclusive sublicense, without the right to sublicense, under the Columbia License, to make, have made, use, offer to sell, sell, import and export Agreement Products in the Territory, including, without limitation, the right to decode Library Compounds.

License Property
Licensor has developed proprietary technologies relating to the design and preparation of encoded compound libraries based upon combinatorial chemistry.  'Licensor Technology' shall mean Existing Licensor Patent Rights, Existing Licensor Know-How, and Licensor Improvements (with some exceptions).

Product means any Agreement Product or Licensees Product.

Agreement Product shall mean any product containing an Agreement Compound, including, without limitation, products for the therapeutic or prophylactic treatment or prevention of diseases and conditions in human beings or animals.

Licensees Product shall mean any product for the therapeutic or prophylactic treatment or prevention of diseases and conditions in human beings containing a Licensee Compound, provided such Licensee Product is not a Combination Product containing both a Licensee Compound and an Agreement Compound.

Active Compound shall mean a Library Compound that demonstrates activity against a specific Target, which Library Compound was found to have such activity at a concentration set forth in the applicable Collaboration Research Plan during screening of one or more Libraries by Licensor in the conduct of the Collaboration or was found to have such activity during screening by or on behalf of Licensee.

Licensor's combinatorial chemistry technology as an important component in our ongoing efforts to accelerate the drug discovery process and to identify lead compounds for development as new therapeutic entities.'

Field of Use
This agreement field relates to assays, compound screening methods and biological research tools used to design, prepare and screen compound libraries against Licensees biological targets.

IPSCIO Record ID: 237211

License Grant
For Licenses in the Diagnostic Imaging Field, the License to Licensor Technology, Licensor grants to the Licensee of the Netherlands an exclusive worldwide license to use the Licensor Technology and Licensor Improvements pursuant to a Collaboration Project and/or a Licensee Project to research, develop, make and use Licensor Leads, Collaboration Leads and Licensee Leads in the Diagnostic Imaging Field and to use in connection with the applicable Collaboration Project and/or Licensee Project the Licensor Technology, Licensor Improvements and Collaboration Results to research, develop and make Licensed Products in the Diagnostic Imaging Field from such Licensor Leads, Collaboration Leads and Licensee Leads.

For License to Licensor Leads, Collaboration Leads and Licensee Leads, Licensor grants an exclusive worldwide license, with the right to grant sublicenses, to use the Licensor Leads, Collaboration Leads and Licensee Leads and Collaboration Results pursuant to a Collaboration Project or a Licensee Project to research, develop, make, have made, use, import and have sold Licensed Products in the Diagnostic Imaging Field.

For the Option in the Licensee Therapeutics Field, the License Option, with regard to any Licensor Lead for which a Collaboration Project exists and for any Collaboration Lead or Licensee Lead, Licensee may extend the license rights granted to the exclusive use of such lead to research, develop, make, have made, use, import and have sold Licensed Products in the Licensee Therapeutics Field and will have a non-exclusive license to use the Licensor Technology in the Licensee Therapeutics Field in connection therewith; provided that such lead is not part of an active Licensor research and development program or that Licensor is not precluded from granting the license because of an agreement with a third party.

License Property
Licensor possesses intellectual property, display technology and expertise relating to the discovery of proteins, peptides and antibodies and other compounds having novel binding properties for therapeutic, diagnostic and other uses.

Licensor Technology shall mean collectively any proprietary peptide, protein and antibody library technology and/or all related materials, data, know-how, inventions and Patent Rights that Licensor owns or controls and has the right to grant licenses to in the Diagnostic Imaging Field existing or arising during and through the Research Term.

Licensor Leads shall mean any peptide, protein or antibody molecules existing as of the Effective Date, including Proteases, Antibodies, Blood Proteins , Cell Surface Receptors·, Signal Transduction Components, and, Viruses,  and any peptide, protein or antibody molecules that Licensor thereafter owns or controls and has the right to grant licenses in the Diagnostic Imaging Field after the Effective Date for so long as Licensee maintains the exclusive license to the Licensor Technology in the Diagnostic Imaging Field, and any data, know-how, inventions and Patent Rights pertaining to such Licensor Leads. Licensor Leads shall not include any Collaboration Leads.

Collaboration Leads shall mean any peptide, protein or antibody molecule and the sequence contained therein and derivatives thereof, resulting from or pertaining to any Collaboration Project commenced during the Research Term and that exist at the time of termination of the Research Term and associated Patent Rights, other than Licensor Leads.

Licensee Leads shall mean any peptide, protein or antibody molecule and the sequence contained therein and derivatives thereof discovered by Licensee after the Research Term using any of the Licensor Technology or Licensor Improvements and associated Patent Rights.

Collaboration Results shall mean any Collaboration Leads and other materials, information, data, and know-how, whether or not patentable, that result from any Collaboration Project that is useful by Licensee in the Collaboration Field or by Licensor in all fields except the Collaboration Field, and any Patent Rights covering inventions resulting from such Collaboration Project, excluding Licensor Technology and Licensor Improvements and Barriers Carrier and Licensee Improvements.

Licensed Product shall mean any product that consists of, includes or was derived from any Licensor Lead, Collaboration Lead or Licensee Lead for which Formal Development has commenced or which arose out of a Collaboration Project.

Field of Use
This agreement is to discover and develop product candidates for use in diagnostic imaging and certain therapeutic fields.

Diagnostic Imaging Field shall mean any in vivo use in medical imaging, including radiopharmaceutical, ultrasound, MRI and X-ray and light imaging.

Licensee possesses intellectual property, technology and expertise relating to the research, development and commercialization of diagnostic imaging products and radiopharmaceuticals.

IPSCIO Record ID: 249766

License Grant
Licensor grants to the French Licensee, an exclusive, worldwide, right and license, within the Territory, to use the Licensor Intellectual Property and Patent Rights with application to the Field to the extent necessary or useful to research, develop, make, have made, use, distribute for sale, promote, market, offer for sale, sell, have sold, import and export Lead Compounds and Products.
License Property
NeoMorph Chemistry means the process, proprietaty to Licensor, of forming libraries and sub-libraries of discrete compounds by coupling a broad set of diverse cores with diverse sets of building blocks employing proprietary mass-coding algorithms.

Licensor Intellectual Property means, individually and collectively, all Inventions that are conceived, discovered, developed, generated, created, made or reduced to practice or tangible medium of expression solely by employees or consultants of Licensor at any time prior to the Effective Date or after the Effective Date; any tangible materials provided by Licensor to Licensee for use in the conduct of the Program, together with, where applicable, any analogs, derivatives, fragments, progeny, sub-cellular constituents or expression products thereof; and the NeoMorph Screening Library, the NeoMorph Focused Libraries, ALIS and QSCD. The Licensor Intellectual Property, however, does not include any know-how, processes, information and data which is, as of the Effective Date or later becomes, generally available to the public.

Derivative Compounds means any analog, homolog or isomer of a Lead Compound, which has an IC50 value against the Screening Target of twenty (20)  micromolar or less, which results from a chemical synthesis program based on the Lead Compounds or is based on structure-activity data of the Lead Compound; provided, that any such program or data is in respect of a target protein from other bacterial or fungal organisms homologous in origin and biological function to the original Screening Target.

Field of Use
The field means preventative, therapeutic and diagnostic uses in humans or animals.

IPSCIO Record ID: 291205

License Grant
By this agreement, Licensor will use its DirectedDiversity Technology to compute a chemical descriptor matrix to describe and map the compounds for which Licensee provides data.  Licensor also will develop a Structure Activity Relationship model based on this descriptor matrix for Hits.  The license during the research period is exclusive.

Licensor grants a worldwide, exclusive license, with right to sublicense, in the Field under such patent to develop, make, have made, use, sell, offer for sale, have sold, import and have imported Licensed Products, provided that Licensor is not contractually prohibited under a written agreement with a third party from granting such an exclusive license. In the event that Licensor is so contractually prohibited from granting such an exclusive license, Licensor shall grant to Licensee as broad a scope of license as it is permitted (for example, a non-exclusive license) and Licensor shall use its reasonable best efforts to negotiate with such third party to remove such contractual prohibition so as to allow Licensor to grant Licensee the foregoing exclusive license under such Licensor Patents.

For the Unblocking License Grant – Licensor grants a worldwide, nonexclusive license, with right to sublicense, to develop, make, have made, use, sell, offer for sale, have sold, import and have imported Licensor Compounds, Derivative Compounds, and Licensed Products, under any Licensor patent rights which would otherwise be infringed by Licensee but for this license.

License Property
Licensor is engaged in discovery research for a variety of biologically active compounds and the development of technologies to facilitate such research, and has patented systems for generating chemical compounds having desired pharmaceutical properties.

DirectedDiversity Technology means Licensor Patents and proprietary know-how that relate to generating and utilizing a DirectedDiversity Chemical Library.

DirectedDiversity(R) Chemi-Informatic Technology uses proprietary computer algorithms to design, select and iteratively refine combinatorial libraries of novel, small-molecule drugs based on screening hits obtained from  Licensor or other screening libraries, target-protein 3D structures, or pharmacophore models derived from lead compounds.

Active Compound means a Licensor Compound or Derivative Compound that has been formally selected by Licensee for preclinical and/or clinical development.

Field of Use
Field means human and animal therapeutic and diagnostic imaging uses of compounds against or acting through Targets. The Field for any particular Target will include all therapeutic indications for compounds acting through Targets, including but not limited to the indications identified in the Research Plan.

Licensee is engaged in research and development of human therapeutic products.  The purpose of this collaboration is to identify qualified lead compounds active against selected targets and suitable for medicinal chemistry optimization that may be developed and commercialized by Licensee.

IPSCIO Record ID: 203459

License Grant
Licensor grants an exclusive, even as to Licensor, license, with the right to sublicense, under Licensors interest in Collaboration Patents, and Collaboration Know-How, in each case solely to develop, make, have made, use, sell, have sold, offer for sale and import Products in the Field in the Territory; provided, however, that Licensor retains such rights under Collaboration Technology as are necessary to perform its obligations under the Research Program.

This agreement also includes Non-Exclusive Cross-Licenses where each Party hereby grants to the other Party a non-exclusive, royalty-free license, without the right to sub-license
(i) under such Partys interest in Collaboration Know-How for the manufacture or formulation of products other than Products, including 'cocktail' and other Combination Products; and
(ii) under such Partys interest in Collaboration Know-How, solely to conduct research in the HCV Field in the Territory.

License Property
Licensor has a research program for the discovery and optimization of nucleoside inhibitors of the NS5b polymerase in hepatitis C virus.

The Collaboration Compound shall mean a Nucleoside that satisfies the chemical and technical requirements set forth, and its Related Compounds and which
(a) is or was synthesized by or for Licensor on or before the Effective Date or during the Research Program Term; or
(b) is a Related Compound to a Collaboration Compound disclosed by Licensor to Licensee pursuant to Identification and Contribution of Collaboration Compounds and which is synthesized by or for Licensee after the Effective Date.

The Collaboration Compound Products shall mean any preparations in final form, bulk form or other form containing as an active pharmaceutical ingredient one or more Selected Compounds.

Field of Use
The Field shall mean all human and animal therapeutic, diagnostic, and prophylactic uses, including, without limitation, the treatment, prevention and prophylaxis of hepatitis C viral infections.

The HCV Field shall mean the treatment of chronic hepatitis C viral infections in humans.

The Collaboration Compound Products are for sale by prescription, over-the-counter or any other method, including without limitation any Combination Product.

IPSCIO Record ID: 211864

License Grant
For the Non-Exclusive Research License to Licensor Base Technology, Licensor grants a non-exclusive, world-wide license under the Base Technology to conduct research and development activities pursuant to the Research Plan, with no right to sublicense.   Licensor also grants the right to sublicense or transfer the rights granted under the Collaboration Technology to Affiliates; and to Third Parties.
License Property
License agreement is for the development of orally bioavailable small-molecule compounds identified through the application of PTC’s proprietary GEMS (Gene Expression Modulation by Small Molecules) technology.

GEMS (Gene Expression Modulation by Small-Molecules) is a novel drug discovery platform technology which enables identification of compounds that target the post-transcriptional regulation of gene expression.

GEMS-UTR (Gene Expression Modulation by Small-Molecules Untranslated Region) is a proprietary screening technology for the identification of small molecules that modulate gene expression by targeting the post-transcriptional control processes that act through the UTRs of mRNA molecules.

The Licensed Product shall mean any Product which incorporates a Collaboration Compound as an active ingredient.  The Collaboration Compound shall mean, on a Target-specific basis, a chemical compound that is synthesized or identified by the Parties, and any metabolites, prodrugs, solvates, including without limitation hydrates, analogs, esters, salts, derivatives, stereoisomers, racemates, tautomers and polymorphs of such chemical compound which are determined to be Active. Collaboration Compound shall include any of a Hit, a Research Compound, a Lead Compound or an IND Candidate.

Field of Use
Field shall mean the prevention, treatment or diagnosis of all diseases or conditions in humans or animals.

This agreement pertains to drug discovery.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.